Adhesion prevention products such as Seprafilm are used by surgeons to manage intraoperative bleeding and reduce scar tissue, which can cause major postsurgical complications and often requires revision or a second surgery. Seprafilm is designed specifically for patients getting an abdominal or pelvic laparotomy.
“While Seprafilm is clinically recognized among surgeons globally, we plan to provide commercial support for the product through our dedicated surgery salesforce and pursue opportunities for expansion in certain countries,” said Wil Boren, president of advanced surgery at Baxter.
The deal is expected to close by the end of the first quarter of 2020. Sales of Seprafilm are expected to be about $100 million in the first year after the deal closes.
Read the full news release here.
More articles on supply chain:
Medtronic warns of potential safety risk for its insulin pumps
Birmingham hospital facing ‘dangerously low’ blood supply
Amazon develops smart shelf that automatically repurchases supplies
